Apellis Pharmaceuticals, Inc.(APLS)

Description: Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

---

Keywords: Medicine Biopharmaceutical Clinical Medicine Organ Systems Eye Inflammatory Diseases Macular Degeneration Chronic Obstructive Pulmonary Disease Pulmonary Disease Copd Hemoglobin Autoimmune And Inflammatory Disease Complement System Paroxysmal Nocturnal Hemoglobinuria Treatment Of Chronic Obstructive Pulmonary Disease Acquired Hemolytic Anemia Geographic Atrophy Hemoglobinuria Intravitreal Administration Intravitreal Injection

---

Home Page: www.apellis.com

APLS Technical Analysis

100 Fifth Avenue
Waltham, MA 02451
United States
Phone: 617 977 5700

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)